SUMMARY Secretion of the neuroendocrine marker neuron-specific enolase by 24 pituitary tumours was measured in maintenance tissue culture. Eleven endocrine-active and 13 "functionless" tumours were defined by measurement of prolactin, growth hormone, luteinising hormone (LH) and follicle stimulating hormone (FSH) secretion rates in vitro and the corresponding plasma hormone levels. Measurement of prolactin secretion provided a clear distinction between true prolactinomas and "functionless" tumours causing hyperprolactinaemia by stalk compression (pseudoprolactinomas). A previous report of LH and/or FSH secretion by the majority of "functionless" tumours was confirmed, but plasma levels of LH and FSH were usually normal. It is argued that LH and FSH are not the major hormones secreted by "functionless" tumours. A high production rate of neuronspecific enolase appears to be characteristic of the cell type from which most "functionless" tumours derive.
are endocrinologically silent. Secretion by "functionless" tumours is, however, predictable because electron microscopy shows the presence of cytoplasmic secretory granules similar to granules containing known hormones in endocrine-active tumours.1 Although the putative hormone secreted by "functionless" tumours is unknown the association of a tumour marker might throw further light on the cell type from which these tumours arise.
Neuron-specific enolase (NSE) is one candidate for such a biochemical marker. As its name implies, NSE is the yy isomer of a glycolytic enzyme present in neurons and their axons, whilst glial cells contain the ax isomer.2 Recent studies have shown that NSE is not confined to neurons and is widely distributed in neuroendocrine tissues including the APUD (amine precursor uptake and decarboxylation) cells of the gut,3 pancreas,34 thyroid,4 lung' and adrenal glands.4 NSE is therefore a cell marker for the diffuse neuroendocrine system4 and is produced by a variety of neuroendocrine tumours. 6 Marangos et al7 reported the presence of NSE in the normal anterior pituitary of man and monkey but did not comment on its distribution according to cell type. Van Noorden et Secretion ofneuron-specific enolase, prolactin, growth hormone, LHandFSHbypituitary tumours in vitro and/or prolactin and 13 "functionless" tumours were defined by plasma hormone levels in conjunction with measurements of hormone secretion rate in vitro.
The prolactin secretion rate was measured in every case in order to distinguish true prolactinomas from "functionless" tumours associated with hyperprolactinaemia, and the GH secretion rate to exclude contamination of tumour tissue by normal pituitary. The 13 tumours ultimately classified as "functionless" were chromophobe adenomas which failed to secrete prolactin or growth hormone in vitro despite the frequent finding of modest hyperprolactinaemia in vivo.
Luteinising hormone (LH) and follicle stimulating hormone (FSH) secretion was measured in this study because Mann-Whitney U test). There was no significant difference in the secretion rate of LH or FSH between prolactin and growth hormone secreting tumours. Low levels of LH secretion by endocrine-active tumours ranged from 01-1 1 mIU/mg/24 h. The secretion rate of LH by "functionless" tumours fell within this range in only three cases and was increased in 10. FSH secretion by five endocrine-active tumours was undetectable and ranged from 0--1-8 mIU/mg/24 h in six. The secretion rate by "functionless" tumours fell within this range in only six cases and was increased in seven. LH secretion was high in all 7 tumours showing high FSH secretion.
In spite of high gonadotrophin secretion in vitro plasma levels of LH were raised in only one patient and of FSH in only four, all of whom were male. 
